Search PubMed⌕ Search

Biomedical subjects

Z Y Han

Publications and source records attributed to Z Y Han.

11 recordsLinked to original sources
PubMed1991

Clinical and laboratory observations on polysaccharide sulphate (PSS) in 282 cases of ischemic cerebrovascular disease.

Polysaccharide sulphate (PSS) is a new heparinoid drug. The therapeutic effect and laboratory findings in the treatment of 282 cases with ischemic cerebrovascular disease by PSS were analysed in this study. In treating patients with acute cerebral infarction, the effective rate (93.2%) and highly effective rate (62.9%) were both significantly higher in comparison with controls. Excellent results were also obtained in treating patients with cerebral infarction at late and sequela stage and patients with transient ischemic attack. Laboratory observations and animal experiments showed that PSS has anticoagulative and vasodilatory effects. It can also reduce blood viscosity and serum lipids. So PSS is an effective drug for the prevention and treatment of ischemic cerebrovascular diseases.

Adult↗
PubMed1989

[Study on follicle growth, ovulation and morphological changes of endometrium by ultrasonic and biochemical measurements].

Daily growth of the follicles before ovulation and the changes of the endometrium after ovulation were recorded in 16 spontaneous menstrual cycles by the ultrasonic and biochemical measurements. The mean diameter of the dominant follicle was 20 mm before ovulation, the mean volume 3.0 ml, and the growth rate of the follicles 1-3 mm/24 h. Ovulation occurred within 24 h of the luteinizing hormone peak and within 48 hours of the blood estrogen peak. The fact that the blood progesterone levels were higher on the day of the LH peak indicated that luteinization of the dominant follicles had already occurred prior to ovulation. Sonographic criteria of the endometrical tissue were obtained after the serial observation. According to the different sonographic appearances, the secretory phase of the endometrial tissue was divided into the early secretory phase, the middle secretory phase and the late secretory phase. The sonographic characterization of the endometrial tissue in the different phases as well as the thickness of the endometrium during the cycles were described. The clinical usefulness of the criteria of the different phases was to evaluate the subsequent luteal function, and facilitate the clinical management of the infertile women. The study confirms that ultrasound can provide a reliable measure in monitoring the follicular growth and ovulation, and observing the morphological changes of the endometrial tissue during the secretory phase. Thus the in vivo differentiation of the endometrial tissue during the secretory phase could be studied non-invasively by means of the ultrasound tissue characterization.

Adult↗
PubMed1989

[Clinical, laboratory and animal experimental observations in treating 288 cases of ischemic cerebrovascular disease with polysaccharide sulfate].

The therapeutic effect and laboratory finding in the treatment of 288 cases of ischemic cerebrovascular disease with PSS were analysed. Positive therapeutic response to PSS in this series of cases was obtained in 92.0% and 62.2% of the treated cases showed excellent results. Effects in the treated patients were better than in the controls. The laboratory findings showed that PSS had obvious anticoagulant effect and decreased blood viscosity and serum contents of lipids. The results of animal experiments showed that PSS had the action of blood dilution, lowering blood viscosity and ameliorating hypercoagulation. PSS was considered to be a prospective, useful drug to prevent and treat ischemic cerebrovascular disease.

Adult↗
PubMed1985

A follow-up study of the efficacy and safety of injectable microencapsulated megestrol acetate and a discussion on its contraceptive mechanism.

A monthly injectable microencapsulated contraceptive was developed by the researchers of the School of Pharmacy of Sichuan Medical College, and a comparative clinical study was undertaken by the Sichuan Cooperative Research Group. It has been found that the microencapsulated compound consisting of 15 mg megestrol acetate and 5 mg estradiol valerate is associated with the lowest incidences of menstrual disturbances and other side effects. This is a follow-up report on the 434 women who used this 'optional' dosage of compound by before-and-after comparisons and by comparisons with two other groups of women: 41 women who were given the compound with the same dosage combination but with microencapsular coat dissolved, and 20-30 women who were using a non-steroidal contraceptive method such as IUDs, barrier or rhythm methods. The microencapsulated compound was highly effective in preventing accidental pregnancies. All except two of the 119 women who discontinued the medication experienced normal menstruation within 3 months. The study did not show changes in blood pressure, liver function, glucose tolerance level and plasma concentration of cholesterol in women using the compound. Cervical smears and breast examination also showed no evidence of epithelial abnormality or breast tumors. This new delivery system of microencapsulated injections affects the cervical mucus function, and inhibits ovulation as well as implantation of fertilized ovum.

Adult↗